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Background: The improved reagent for measuring estradiol (E2), the ST AIA-PACK iE2 reagent, has a higher specificity
for the measurement of E2 levels than the original ST AIA-PACK E2 reagent, because of its lower cross-reactivity with
estrone (E1). As we had E2 data obtained with either of the reagents, we analyzed changes in E1 and E2 levels during
follicle development.
Methods: The study included 14371 serum hormone measurements from 4412 patients who underwent oocyte retrieval
or frozen/thawed embryo transfer in natural cycle in vitro fertilization in Shinbashi YUME clinic, Tokyo, between June
2011 and May 2014. The age of the patients ranged from 24 to 48 year (mean and standard deviation, 39.8 ± 4.0 year).
Patients were categorized into three age groups (<38 year, 38–40 year, and >40 year) and into 10 groups of largest follicle
diameter from 11 to 20 mm, with 1-mm intervals. Serum E2 levels were measured in the follicular phase with either the
ST AIA-PACK E2 reagent or the ST AIA-PACK iE2 reagent, and the data were compared. Also, for 26 randomly selected
samples, E2 was measured using both reagents, together with E1 and E3, and the E1/E2 ratios were compared.
Results: E2 concentrations measured with the ST AIA-PACK iE2 reagent were significantly lower than those measured
with the ST AIA-PACK E2 reagent in the largest follicle diameter category of 11–17 mm in the <38 year group, in the
largest follicle diameter category of 11–18 mm in the 38–40 year group, and in the largest follicle diameter category
of 11–15 mm in the >40 year group. The serum E1/E2 ratio in the 26 samples was 3.4 ± 1.1 and 0.7 ± 0.1 in the early
follicular phase and in the ovulatory phase, respectively.
Conclusions: The difference between the E2 concentrations measured with the ST AIA-PACK E2 reagent and the ST
AIA-PACK iE2 reagent tended to decrease as the follicle diameter increased, particularly in the older patients, which
suggests E1 secretion is more abundant in the early follicular phase and in younger patients than in the ovulatory
phase and in older patients.
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The serum estradiol (E2) concentration is used to evaluate
follicle maturation. This measurement is essential to predict
the timing of ovulation when treating infertility patients. As
the date of ovulation approaches, the E2 level changes dy-
namically day-by-day, particularly in natural cycle in vitro
fertilization (IVF). In pre-menopausal women, E2 is mainly
secreted by granulosa cells in the follicles. As these cells
divide and proliferate within a follicle, increasing in number* Correspondence: t-segawa@yumeclinic.net
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creativecommons.org/publicdomain/zero/1.0/as the follicle grows, the E2 level also increases. Thus, the
E2 concentration is a good index of follicular maturation.
Menopausal and post-menopausal women, as well as obese
women, have elevated serum levels of estrone (E1), and E1
is also secreted by tissues other than the ovary [1–6]. How-
ever, the action and role of E1 and its secretion dynamics
are still not well understood.
In patients undergoing infertility treatment using assisted
reproductive technologies in our clinic, the E2 level is mea-
sured using an enzyme immunoassay analyzer (AIA-1800
or AIA-2000; TOSOH Corporation, Tokyo, Japan). The E2
levels are measured in real time using a competitivearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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immunoassay (FEIA) method. It is performed entirely
within a supplied test cup (ST AIA-PACK E2 test kit or
ST AIA-PACK iE2 test kit). E2 present in the test sample
competes with alkaline phosphatase-labeled E2 in the cup
for a limited number of binding sites on E2-specific anti-
bodies immobilized on magnetic beads. The beads are
washed to remove any unbound enzyme-labeled E2 and
are then incubated with a fluorogenic substrate. The E2
concentration in the sample is calculated based on the
time the enzyme takes to produce a fluorescent substance.
Serum E2 levels are measured in approximately 20 min.
Initially, we used the ST AIA-PACK E2 test kit (herein-
after referred to as “the ST AIA-PACK E2 reagent”), but
in August 2012, we changed to the ST AIA-PACK iE2 test
kit (hereinafter referred to as the “ST AIA-PACK iE2 re-
agent). The ST AIA-PACK iE2 reagent uses CRM577, a
reference material certified by the Institute for Reference
Materials and Measurements, for calibration. Results with
the ST AIA-PACK iE2 reagent correlate well with results
of isotope dilution-gas chromatography/mass spectrom-
etry. Additionally, the ST AIA-PACK iE2 reagent uses an
antibody with a higher E2 specificity than the ST AIA-
PACK E2 reagent, which uses a polyclonal antibody gener-
ated by immunizing a rabbit with antigen and purifying its
blood. For the ST AIA-PACK iE2 reagent, the antibody is
obtained by exenterating the spleen of an antigen-
immunized rabbit, isolating the B cells, and creating hy-
bridoma cells by fusing the B cells with myeloma cells;
these hybridoma cells can divide indefinitely, and the cells
that generate an antibody with a higher E2 specificity are
then selected. Table 1 shows the cross-reactivity of both
reagents. The ST AIA-PACK iE2 reagent is shown to be
more specific than the ST AIA-PACK E2 reagent as it has
a much lower cross-reactivity with E1 and estriol (E3). In
other words, E1 and E3 secretion is more likely to be in-
cluded in the serum E2 concentration measured with the
ST AIA-PACK E2 reagent than in that measured with the
STAIA-PACK iE2 reagent.
We hypothesized that a comparison of the measure-
ments obtained by the two different reagents would allowTable 1 Cross-reactivity of ST AIA-PACK E2 and ST AIA-PACK iE2
reagents
Cross-reactivity (mol %)
Substance ST AIA-PACK E2 reagent ST AIA-PACK iE2 reagent
Estradiol (E2) 100 100
Estrone (E1) 7.2 1.1
Estriol (E3) 4.9 0.25
Please refer to the following websites for additional data. (The text is in




480201_13A2X00174000006_A_04_01.pdfus to indirectly evaluate the serum levels of hormones other
than E2 with which the ST AIA-PACK E2 reagent had high
cross-reactivity. We carried out a statistical analysis and
compared the E2 measurements obtained with the STAIA-
PACK E2 reagent and ST AIA-PACK iE2 reagent according
to follicle size in a natural cycle IVF setting. Changes in the
E2 levels observed during the course of infertility treatment
are reported. We also describe cases in which the different
cross-reactivity to E1 and E3 between the two reagents was
reflected in the difference in the measured concentrations.
Methods
A total of 14371 serum hormone data measurements from
4412 women who underwent oocyte retrieval or frozen/
thawed embryo transfer in natural cycle IVF in our clinic
between June 2011 and May 2014 were included in this
study. These patients were treated with IVF or intracyto-
plasmic sperm injection (ICSI) because of female-related
(12.1 %), male-related (28.0 %), or unexplained (59.8 %) is-
sues. The patients’ age ranged from 24 to 48 year (mean
age and standard deviation, 39.8 ± 4.0 year). The average
body mass index was 20.7 ± 2.6 (range: 14.8–41.0). Most
patients were Japanese (99.2 %), followed by other Asians
(0.7 %) and other ethnic groups (0.1 %). Samples were taken
from the patients between day 8 and day 20 of their men-
strual cycle, before the onset of the luteinizing hormone
(LH) surge, i.e., when the LH level was <20 IU/L and the
progesterone (P4) level was <1.0 ng/mL. Cases were ex-
cluded if either of the following criteria were met: 1) more
than two follicles ≥11 mm in diameter were observed on
ultrasonography and 2) the diameter of the largest follicle
was ≥21 mm. Approval of this study was obtained from the
independent Institutional Review Board of Shinbashi
YUME Clinic (SYC2014-8, approved 1 July, 2014). All pa-
tients received detailed information about the proposed
treatment. Written informed consent was obtained from all
participants; they also agreed that their de-identified data
could be used for research purposes.
Serum concentrations of E2, LH, follicle-stimulating hor-
mone (FSH), and P4 were measured in all patients on the
AIA-1800 or AIA-2000 analyzer using the FEIA method.
Follicle size during the natural cycle, with no administration
of ovulation-inducing drugs, was determined by ultrasound
examination using the HI VISION AVIUS system (Hitachi
Medical Corporation, Tokyo, Japan). Follicle maturation
was considered complete when serum E2 levels were
≥200 pg/mL and the diameter of the largest follicle was
≥18 mm.
When the follicles reached maturation, a gonadotropin-
releasing hormone (GnRH) agonist (Suprecur, Mochida
Pharmaceutical Co., LTD., Tokyo, Japan) was administered
to trigger the endogenous LH surge, and oocytes were re-
trieved 34–36 h later. The retrieved oocytes were insemi-
nated by conventional methods or ICSI. They were cultured
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transferred as a fresh embryo or vitrified for a later frozen/
thawed transfer. For the frozen/thawed transfer carried out
in the natural cycle, serum hormone measurement and the
ultrasound examination were performed as in the oocyte re-
trieval cycle; the embryo was thawed 4–5 days after ovula-
tion, and the blastocyst was transferred. Oocyte retrieval,
embryo transfer, and embryo culture were all carried out
following the methods stipulated by Teramoto et al. [7] and
Kato et al. [8, 9].
Serum E2 concentrations for the 14371 samples ob-
tained during the oocyte retrieval cycles and frozen/
thawed embryo transfer cycles, measured with the ST
AIA-PACK E2 reagent or STAIA-PACK iE2 reagent, were
categorized by the largest follicle diameter (10 groups,
from 11 to 20 mm, with 1-mm intervals) and by age (<38
year, 38–40 year, and >40 year). Since most of the patients
in our clinic have histories of failed IVF treatment in other
institutions, our patient population tends to be much
older than that of other institutions. For this reason, pa-
tients in the <38 year, 38–40 year, and >40 year categories
were considered young, older, and old, respectively. In
total, 4032 measurements were in the <38 year group
(1256 and 2776 with the ST AIA-PACK E2 reagent and
ST AIA-PACK iE2 reagent, respectively), 3740 were in the
38–40 year group (1307 and 2433 with the ST AIA-PACK
E2 reagent and ST AIA-PACK iE2 reagent, respectively),
and 6599 were in the >40 year group (2720 and 3879 with
the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 re-
agent, respectively). The serum E2 levels measured with
each reagent were then compared within each follicle size
category. Similarly, the serum E2 concentration and serum
FSH concentration were compared between the three age
groups in each follicle size category. Furthermore, serum
E2 (measured with both reagents), serum E1, and serum
E3 concentrations (measured by the radioimmunoassay
method; BML Inc., Tokyo, Japan) were measured in 12
randomly selected cases in the early follicular phase and
in 14 randomly selected cases in the ovulatory phase, and
the measurements in the two phases were compared. All
data were analyzed using the t-test by JMP 11.2 (SAS In-
stitute, Cary, NC, USA). P < 0.01 was considered to indi-
cate statistical significance.
Results
Table 2 shows the comparison between the serum E2 con-
centrations measured with the two reagents. The data are
categorized by age and largest follicle diameter. In the <38
year group, E2 concentrations measured with the ST AIA-
PACK iE2 reagent were significantly lower than those
measured with the ST AIA-PACK E2 reagent in the lar-
gest follicle diameter categories ranging from 11 to
17 mm. However, in the largest follicle diameter categories
from 18 to 20 mm, the E2 concentrations measured usingthe two reagents did not differ. In the 38–40 year group,
the E2 concentrations measured with the ST AIA-PACK
iE2 reagent were significantly lower than those measured
with the ST AIA-PACK E2 reagent in the largest follicle
diameter categories ranging from 11 to 18 mm, but no sig-
nificant difference was noted for the categories from 19 to
20 mm. In the >40 year group, the E2 concentrations mea-
sured with the ST AIA-PACK iE2 reagent were signifi-
cantly lower than those measured with the ST AIA-PACK
E2 reagent in the largest follicle diameter categories ran-
ging from 11 to 15 mm, but no significant difference was
noted for the categories from 16 to 20 mm. Table 3 shows
the comparison of serum E2 concentrations (measured
with the ST AIA-PACK iE2 reagent) and serum FSH con-
centrations between the age groups for each largest follicle
diameter category. There were four patterns of significant
differences between the three age groups. When focusing
on the <38 year and the >40 year groups, serum E2 con-
centrations were significantly higher in the older age
group than in the younger age group for the 11 mm to
18 mm largest follicle diameter categories, but there was
no significant difference between the groups for the
19 mm and 20 mm categories. Serum FSH concentrations
were significantly higher in the older age group for all lar-
gest follicle diameter categories. Table 4 shows the com-
parison of the mean serum estrogen concentrations (E1,
E2, and E3) in 12 randomly selected cases from the early
follicular phase and 14 randomly selected cases from the
ovulatory phase. The ratios of serum E2 concentrations
measured with the ST AIA-PACK iE2 reagent to those
measured with the ST AIA-PACK E2 reagent were 2.9 ±
0.6 and 0.9 ± 0.1 for the early follicular phase group and
the ovulatory phase group, respectively (P < 0.01). Further-
more, the serum E1 concentration to serum E2 concentra-
tion ratios measured with the ST AIA-PACK iE2 reagent
(E1/E2) were 3.4 ± 1.1 and 0.7 ± 0.1 in the early follicular
phase group and the ovulatory phase group, respectively
(P < 0.01). Serum E3 concentrations were below the detec-
tion range in both groups.
Discussion
In the present study, we analyzed the differences in estro-
gen concentration measurements according to the reagent
used, considering the different properties of the two re-
agents used for measuring serum E2 concentrations. The
improved specificity of the new E2 measuring reagent
from TOSOH Corp. is attributable to the use of a mono-
clonal antibody rather than a polyclonal antibody. There-
fore, we presumed that the content of estrogen besides E2
(mainly E1) could be measured indirectly by analyzing the
differences in measurements obtained using the ST AIA-
PACK E2 reagent and the ST AIA-PACK iE2 reagent. We
could not measure E2 in all the 14371 samples using both
the ST AIA-PACK E2 reagent and the AIA-PACK iE2




Age <38 year (n = 4032) Age 38–40 year (n = 3740) Age >40 year (n = 6599)
11 mm E2 reagent (n = 125) 99.9 ± 32.6a E2 reagent (n = 99) 101.5 ± 30.9a E2 reagent (n = 195) 113.4 ± 45.3a
iE2 reagent (n = 191) 68.0 ± 34.7a iE2 reagent (n = 147) 71.0 ± 40.4a iE2 reagent (n = 220) 86.8 ± 51.8a
12 mm E2 reagent (n = 114) 105.8 ± 35.6a E2 reagent (n = 122) 113.5 ± 40.9a E2 reagent (n = 226) 125.3 ± 48.2a
iE2 reagent (n = 234) 80.4 ± 41.8a iE2 reagent (n = 177) 84.7 ± 42.9a iE2 reagent (n = 297) 102.8 ± 53.5a
13 mm E2 reagent (n = 127) 122.2 ± 44.6a E2 reagent (n = 114) 135.9 ± 49.0a E2 reagent (n = 242) 142.2 ± 49.1a
iE2 reagent (n = 241) 87.3 ± 42.6a iE2 reagent (n = 200) 96.7 ± 44.6a iE2 reagent (n = 284) 116.1 ± 61.2a
14 mm E2 reagent (n = 125) 130.7 ± 38.8a E2 reagent (n = 125) 155.2 ± 57.4a E2 reagent (n = 234) 166.6 ± 59.8a
iE2 reagent (n = 246) 100.3 ± 51.7a iE2 reagent (n = 182) 115.8 ± 58.6a iE2 reagent (n = 313) 126.1 ± 64.0a
15 mm E2 reagent (n = 118) 168.0 ± 57.0a E2 reagent (n = 154) 168.8 ± 60.2a E2 reagent (n = 313) 187.0 ± 70.6a
iE2 reagent (n = 268) 132.6 ± 64.2a iE2 reagent (n = 238) 150.2 ± 66.5a iE2 reagent (n = 407) 170.6 ± 76.5a
16 mm E2 reagent (n = 134) 186.7 ± 67.8a E2 reagent (n = 173) 195.4 ± 60.0a E2 reagent (n = 351) 210.4 ± 64.6
iE2 reagent (n = 287) 160.0 ± 77.9a iE2 reagent (n = 222) 177.0 ± 78.2a iE2 reagent (n = 444) 197.4 ± 79.5
17 mm E2 reagent (n = 151) 228.5 ± 66.2a E2 reagent (n = 158) 236.6 ± 64.0a E2 reagent (n = 351) 231.8 ± 61.1
iE2 reagent (n = 322) 200.2 ± 85.7a iE2 reagent (n = 282) 216.5 ± 78.5a iE2 reagent (n = 489) 222.3 ± 86.6
18 mm E2 reagent (n = 151) 241.0 ± 75.0 E2 reagent (n = 143) 257.3 ± 60.9a E2 reagent (n = 348) 255.9 ± 59.2
iE2 reagent (n = 323) 229.2 ± 85.4 iE2 reagent (n = 356) 233.5 ± 88.9a iE2 reagent (n = 529) 247.0 ± 82.2
19 mm E2 reagent (n = 102) 253.4 ± 66.1 E2 reagent (n = 112) 260.8 ± 68.2 E2 reagent (n = 230) 259.2 ± 64.6
iE2 reagent (n = 242) 249.6 ± 78.0 iE2 reagent (n = 273) 256.0 ± 79.5 iE2 reagent (n = 368) 261.0 ± 83.5
20 mm E2 reagent (n = 109) 275.2 ± 72.2 E2 reagent (n = 107) 279.9 ± 75.1 E2 reagent (n = 230) 281.5 ± 74.2
iE2 reagent (n = 422) 275.6 ± 95.2 iE2 reagent (n = 356) 285.1 ± 88.0 iE2 reagent (n = 528) 280.6 ± 92.0
Data are presented as mean ± standard deviation
aSignificant differences in serum E2 concentration were found between measurements performed using the ST AIA-PACK E2 reagent and the ST AIA-PACK iE2
reagent (P <0.01)
E2 estradiol, E2 reagent ST AIA-PACK E2 reagent, iE2 reagent ST AIA-PACK iE2 reagent
Table 3 E2 and FSH concentrations in the three age groups, classified according to follicle size
Diameter of the
largest follicle
Serum E2 (pg/mL) measured by iE2 reagent Serum FSH (mIU/mL)
(n = 9088) (n = 9088)
Age <38 year Age 38–40 year Age >40 year Age <38 year Age 38–40 year Age >40 year
11 mm 68.0 ± 34.7a 71.0 ± 40.4a 86.8 ± 51.8a 8.6 ± 2.4b 9.5 ± 4.6 10.9 ± 6.8b
12 mm 80.4 ± 41.8a 84.7 ± 42.9a 102.8 ± 53.5a 8.4 ± 2.4a 8.8 ± 3.0a 11.1 ± 7.1a
13 mm 87.3 ± 42.6a 96.7 ± 44.6a 116.1 ± 61.2a 7.9 ± 2.3a 8.3 ± 3.2a 10.3 ± 7.0a
14 mm 100.3 ± 51.7c 115.8 ± 58.6c 126.1 ± 64.0c 7.4 ± 1.9c 8.5 ± 3.5c 9.9 ± 8.5c
15 mm 132.6 ± 64.2d 150.2 ± 66.5d 170.6 ± 76.5d 7.3 ± 2.3c 8.3 ± 3.7c 8.8 ± 4.3c
16 mm 160.0 ± 77.9a 177.0 ± 78.2a 197.4 ± 79.5a 7.1 ± 2.5a 7.7 ± 3.6a 9.0 ± 5.2a
17 mm 200.2 ± 85.7b 216.5 ± 78.5 222.3 ± 86.6b 6.8 ± 2.2d 7.7 ± 3.1d 8.8 ± 6.0d
18 mm 229.2 ± 85.4b 233.5 ± 88.9 247.0 ± 82.2b 6.6 ± 2.3d 7.2 ± 2.8d 8.5 ± 5.1d
19 mm 249.6 ± 78.0 256.0 ± 79.5 261.0 ± 83.5 6.3 ± 2.3a 6.8 ± 2.3a 8.3 ± 6.4a
20 mm 275.6 ± 95.2 285.1 ± 88.0 280.6 ± 92.0 6.5 ± 2.2a 6.8 ± 2.3a 7.8 ± 4.0a
Data are presented as mean ± standard deviation
aSignificant differences were found between the <38 year group and the >40 year group, as well as between the 38–40 year group and the >40 year
group (P < 0.01)
bSignificant differences were found between the <38 year group and the >40 year group (P < 0.01)
cSignificant differences were found between the <38 year group and the 38–40 year group, as well as between the <38 year group and the >40 year
group (P < 0.01)
dSignificant differences were found among all three age groups (P < 0.01)
E2 estradiol, FSH follicle-stimulating hormone, iE2 reagent ST AIA-PACK iE2 reagent
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Table 4 Comparison of estrogen measurements in the early follicular phase and the ovulatory phase
Early follicular phase Ovulatory phase
(n = 12) (n = 14)
Serum E2 (pg/mL)
Measured with ST AIA-PACK E2 reagent (A) 58.7 ± 7.9 245.4 ± 50.5
Measured with ST AIA-PACK iE2 reagent (B) 21.3 ± 4.7 262.9 ± 54.2
(A)/(B) 2.9 ± 0.6a 0.9 ± 0.1a
Serum E1 (pg/mL) 68.0 ± 13.9 191.1 ± 51.9
E1/E2 (measured with A) 3.4 ± 1.1a 0.7 ± 0.1a
Serum E3 (pg/mL)b <5.0 <5.0
Data are presented as mean ± standard deviation
aSignificant differences were found between the early follicular phase and the ovulatory phase groups (P <0.01)
bSerum E3 concentrations were below the detection range for both groups
E1 estrone, E2 estradiol, E3 estriol
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would have been very expensive. Instead, we measured E2
(using both reagents), E1, and E3 at the same time in a
few samples, analyzed the differences, and compared the
E1 to E2 ratios. The E1/E2 ratio was high in the samples
taken from the early follicular phase and there was a sig-
nificant difference between the concentrations measured
with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2
reagent, suggesting that the concentration of E1 was high
in these samples. In samples taken during the ovulatory
phase, the E1/E2 ratio was small and there was only a
small difference in the concentrations measured with the
ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent,
indicating a lower concentration of E1 in these samples.
The LH surge is triggered by positive feedback from
the hypothalamic-pituitary axis, by the increase in estro-
gen levels in the late follicular phase [10]. If a decrease
in serum E1 causes the E2/E1 ratio to increase in the
ovulatory phase (follicle diameter, 19–20 mm), as seen
in the current study, this phenomenon may trigger the
onset of the LH surge. Conversely, the onset of the LH
surge may be suppressed when E1 secretion is high (fol-
licle diameter, ≤18 mm). The possible role of E1 secre-
tion in the mid-to-late follicular phase in maintaining
follicle development by suppressing the LH surge until
the follicle is fully matured is extremely interesting. In
the >40 year group however, the difference in the serum
E2 measurements observed between the two reagents
disappeared after the mid-follicular phase (follicle diam-
eter, 16 mm) and a relative increase in E2 (or decrease
in E1) was observed. In older infertility patients, prema-
ture elevation of serum LH levels is often observed,
before the follicle is fully developed and the premature
LH surge arrests follicular growth. In these situations,
good mature oocytes cannot be obtained. Aging is
known to affect pulsatile GnRH secretion and the pituit-
ary reaction [11]. In the present study, E1 decrease oc-
curred earlier in the >40 year group than in the youngerage groups. In the ≤16 mm follicle diameter category,
the serum E2 levels were significantly higher in the >40
year group than in the younger age groups (Table 3).
Several reports describe an increase in the serum E2
concentration in the follicular phase of older women
[12–15]. A decrease in serum inhibin B in older women
causes an increase in FSH secretion through negative
feedback, which in turn stimulates the granulosa cells in
the ovary, resulting in an elevated serum E2 level [12,
14, 15]. Welt et al. also showed that the androstene-
dione/E1 ratio decreased in older women in the early-
to-mid follicular phase [16]. Androstenedione is con-
verted to E1 by the enzymatic activity of aromatase [17],
which also converts testosterone into E2. Therefore, aro-
matase activity in the ovary may increase in older
women. In this study, there was no difference in the E2
levels measured with the ST AIA-PACK E2 reagent and
ST AIA-PACK iE2 reagent in the follicle diameter cat-
egories from 16 to 20 mm in the >40 year group, sug-
gesting that E1 levels had decreased (Table 2).
There are many reports on the association of E1 with
estrogen-dependent breast cancer tumor growth and
coronary artery disease [18–20]. The bioactivity of E1 is
considered weaker than that of E2 [21]. Kushnir et al. ex-
amined the E1 and E2 concentrations in follicular fluid (FF)
in the early follicular phase and at oocyte retrieval and
found a more than 10-fold higher E1/E2 ratio in the early
follicular phase than at oocyte retrieval. They also showed
that androstenedione concentrations in the early follicular
phase were approximately 60 times greater than those mea-
sured at oocyte retrieval [22]. Costa et al. measured hor-
mone concentrations in the FF at oocyte retrieval, and
compared FF in the follicles containing a mature and an
immature oocyte. The E2 and testosterone levels were sig-
nificantly lower in the FF containing mature oocytes than
in the FF containing immature oocytes, but there was no
significant difference in E1 and progesterone levels between
the two kinds of FF [23]. McNatty et al. examined hormone
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and found that E1/E2 ratio was similar in the early, mid,
and late follicular phases, but the androstenedione/E1 ra-
tio decreased as the follicular phase progressed from the
early, mid, to late phase. They also found that the E1/E2
ratio was lower in blood samples taken from the veins in
the ovary containing a follicle ≥8 mm than in samples
taken from the veins in the ovary not containing a follicle
≥8 mm [24]. While there are several reports on the E1
concentration in the FF, the role of E1 in follicle develop-
ment has not been reported. Although the present study
is an indirect data analysis, the shift in the secretion level
of estrogen (E2 and E1) is of great significance. The E1/E2
ratio, in addition to the change in follicle size, might play
an important role in follicle development and maturation
and ovulation of the oocyte.
Conclusions
The present study revealed a shift in estrogen secretion
during follicle development. In general, fertility centers use
ovulation-inducing drugs to have multiple follicles develop,
thus making it impossible to measure the hormonal con-
centrations per single dominant follicle. We, on the other
hand, treat patients with the natural cycle protocol, which
does not require the use of ovulation-inducing drugs. The
timing of ovulation was determined by measuring the
diameter of the developing dominant follicle by ultrasonog-
raphy and the serum E2 concentrations each time the pa-
tient visited the clinic. Therefore, we could accumulate a
large amount of data, and we believe this kind of data is
very valuable. We also found that the difference between
the E2 concentrations measured with the STAIA-PACK E2
reagent and the ST AIA-PACK iE2 reagent tended to de-
crease as the follicle diameter increased, particularly in the
older patients, which suggests that E1 is more abundant in
the early follicular phase and in younger patients than in
the ovulatory phase and in older patients. We are planning
to extend the scope of the study and examine various as-
pects such as the relationship between the level of estrogen
and oocyte quality, and their influence on pregnancy.
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